These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33568538)

  • 41. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
    Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
    Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease.
    Mattsson N; Eriksson O; Lindberg O; Schöll M; Lampinen B; Nilsson M; Insel PS; Lautner R; Strandberg O; van Westen D; Zetterberg H; Blennow K; Palmqvist S; Stomrud E; Hansson O
    Neurobiol Aging; 2018 Nov; 71():81-90. PubMed ID: 30107289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions.
    Ohm TG; Scharnagl H; März W; Bohl J
    Acta Neuropathol; 1999 Sep; 98(3):273-80. PubMed ID: 10483785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of Uncommon, Noncoding Variants in the APOE Region With Risk of Alzheimer Disease in Adults of European Ancestry.
    Blue EE; Cheng A; Chen S; Yu CE;
    JAMA Netw Open; 2020 Oct; 3(10):e2017666. PubMed ID: 33090224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
    Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
    Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype.
    Thambisetty M; An Y; Nalls M; Sojkova J; Swaminathan S; Zhou Y; Singleton AB; Wong DF; Ferrucci L; Saykin AJ; Resnick SM;
    Biol Psychiatry; 2013 Mar; 73(5):422-8. PubMed ID: 23022416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
    Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential Effects of the Interaction Between the Education and APOE ε4 Allele on Amyloid-beta Retention and Memory Performances in Cognitively Normal Older Adults and Alzheimer's Disease Patients.
    Kang DW; Wang SM; Na HR; Lee CU; Baek IH; Lim HK
    Curr Alzheimer Res; 2020; 17(11):1023-1032. PubMed ID: 33372875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in Nutrient Intake and Diet Quality Between Non-Hispanic Black and Non-Hispanic White Men in the United States.
    Thompson TL; Singleton CR; Springfield SE; Thorpe RJ; Odoms-Young A
    Public Health Rep; 2020; 135(3):334-342. PubMed ID: 32250708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.
    Mecca AP; Barcelos NM; Wang S; Brück A; Nabulsi N; Planeta-Wilson B; Nadelmann J; Benincasa AL; Ropchan J; Huang Y; Gelernter J; Van Ness PH; Carson RE; van Dyck CH
    Neurobiol Aging; 2018 Jan; 61():207-214. PubMed ID: 29111487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints.
    Cavedo E; Chiesa PA; Houot M; Ferretti MT; Grothe MJ; Teipel SJ; Lista S; Habert MO; Potier MC; Dubois B; Hampel H; ;
    Alzheimers Dement; 2018 Sep; 14(9):1204-1215. PubMed ID: 30201102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging.
    Lopes Alves I; Heeman F; Collij LE; Salvadó G; Tolboom N; Vilor-Tejedor N; Markiewicz P; Yaqub M; Cash D; Mormino EC; Insel PS; Boellaard R; van Berckel BNM; Lammertsma AA; Barkhof F; Gispert JD
    Alzheimers Res Ther; 2021 Apr; 13(1):82. PubMed ID: 33875021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden.
    Ramanan VK; Heckman MG; Przybelski SA; Lesnick TG; Lowe VJ; Graff-Radford J; Mielke M; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P;
    J Alzheimers Dis; 2022; 88(4):1615-1625. PubMed ID: 35811524
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
    Johnson KA; Sperling RA; Gidicsin CM; Carmasin JS; Maye JE; Coleman RE; Reiman EM; Sabbagh MN; Sadowsky CH; Fleisher AS; Murali Doraiswamy P; Carpenter AP; Clark CM; Joshi AD; Lu M; Grundman M; Mintun MA; Pontecorvo MJ; Skovronsky DM;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S72-83. PubMed ID: 23375563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories.
    Lopresti BJ; Campbell EM; Yu Z; Anderson SJ; Cohen AD; Minhas DS; Snitz BE; Royse SK; Becker CR; Aizenstein HJ; Mathis CA; Lopez OL; Klunk WE; Tudorascu DL
    Neurobiol Aging; 2020 Oct; 94():111-120. PubMed ID: 32603776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.
    Nordberg A; Carter SF; Rinne J; Drzezga A; Brooks DJ; Vandenberghe R; Perani D; Forsberg A; Långström B; Scheinin N; Karrasch M; Någren K; Grimmer T; Miederer I; Edison P; Okello A; Van Laere K; Nelissen N; Vandenbulcke M; Garibotto V; Almkvist O; Kalbe E; Hinz R; Herholz K
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):104-14. PubMed ID: 22961445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.